Randomised double-blind, placebo-controlled Phase III study of APD421 (amisulpride for IV injection) as combination prophylaxis against post-operative nausea and vomiting in high-risk patients
Laufzeit: 01.01.2015 - 31.12.2015
Kurzfassung
Amisulpride is a dopamine (D2 and D3 receptor) antagonist, approved in the treatment of psychosis since 1996. Beside the antidepressant and antipsychotic properties of amisulpride, the drug also has anti-emetic potential. An international multi-center study. 32 subjects were enrolled in Mainz.
